.Attributes Medication, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after a typical follow-up of 11 months, people with metastatic intestinal tumors that obtained biomarker-matched therapies based upon distributing lump DNA profiling presented a greater clinical advantage than those acquiring unmatched therapy.